Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Immunotherapy for Grass and Olive Allergy
NCT04891237Phase 3Recruiting
- Sponsor
- Inmunotek
- Start
- Jun 2021
- Primary completion
- Jan 2026
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of MG01 + T517 in allergic rhinitis (AR), Rhinoconjunctivitis (RC), allergic asthma, sponsored by Inmunotek. Started Jun 2021; status: recruiting.
02
Drugs
MG01 + T517
03
Conditions
allergic rhinitis (AR)Rhinoconjunctivitis (RC)allergic asthma
Beyond the preview
Go deeper on NCT04891237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891237.